Inno-Gene SA
WSE:IGN
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
N/A
N/A
|
Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one IGN stock under the Base Case scenario is 1.96 PLN. Compared to the current market price of 5.04 PLN, Inno-Gene SA is Overvalued by 61%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Inno-Gene SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for IGN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Inno-Gene SA
Balance Sheet Decomposition
Inno-Gene SA
Current Assets | 3m |
Cash & Short-Term Investments | 1.6m |
Receivables | 1.4m |
Other Current Assets | 14k |
Non-Current Assets | 2.5m |
Long-Term Investments | 1.8m |
PP&E | 660k |
Intangibles | 7k |
Other Non-Current Assets | 72k |
Current Liabilities | 2.5m |
Accounts Payable | 376k |
Accrued Liabilities | 85k |
Short-Term Debt | 30k |
Other Current Liabilities | 2m |
Non-Current Liabilities | 203k |
Other Non-Current Liabilities | 203k |
Earnings Waterfall
Inno-Gene SA
Revenue
|
462k
PLN
|
Cost of Revenue
|
-666k
PLN
|
Gross Profit
|
-204k
PLN
|
Operating Expenses
|
-2.4m
PLN
|
Operating Income
|
-2.6m
PLN
|
Other Expenses
|
-3.5m
PLN
|
Net Income
|
-6.1m
PLN
|
Free Cash Flow Analysis
Inno-Gene SA
PLN | |
Free Cash Flow | PLN |
IGN Profitability Score
Profitability Due Diligence
Inno-Gene SA's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Inno-Gene SA's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
IGN Solvency Score
Solvency Due Diligence
Inno-Gene SA's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Inno-Gene SA's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IGN Price Targets Summary
Inno-Gene SA
Dividends
Current shareholder yield for IGN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Inno Gene SA engages in the management of startup biotechnology companies. The company is headquartered in Poznan, Woj. Wielkopolskie. The company went IPO on 2011-02-08. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.
Officers
The intrinsic value of one IGN stock under the Base Case scenario is 1.96 PLN.
Compared to the current market price of 5.04 PLN, Inno-Gene SA is Overvalued by 61%.